Introduction The programmed death 1 antibodies (PD-1 Ab) nivolumab and pembrolizumab
improve overall survival (OS) in advanced non–small-cell lung cancer (NSCLC). We …

Objectives To describe the treatment patterns and determine the effectiveness and safety of
nivolumab treatment for non-small cell lung cancer (NSCLC) in real-world setting in Japan …

Purpose Immune checkpoint inhibitors (ICI) have shown marked responses in patients with
non-small cell lung cancer (NSCLC) in clinical trials. However, because such trials comprise …

Highlights•Administering nivolumab may challenge NSCLC patients with IIP.•We performed
a multicenter phase-II trial to assess nivolumab's efficacy and safety.•The 6 months PFS rate …

Background and Objective Although anti-programmed cell death protein 1 (PD-1) antibodies
have exerted remarkable anticancer activity in non-small cell lung cancer (NSCLC), it …

Introduction The real-world effectiveness of combination treatment with cytotoxic
chemotherapy and programmed cell death protein-1 or programmed death-ligand 1 inhibitor …

Simple Summary The benefit of programmed death-1/programmed death ligand-1 (PD-1/PD-
L1) immunotherapy, particularly of nivolumab, pembrolizumab and atezolizumab, in the …

Background Treatment of oncogene-addicted non-small cell lung cancer (NSCLC) has been
changed by the advent of tyrosine kinase inhibitors (TKIs). Albeit great benefits are achieved …

Background PD-1 inhibitors have been routinely used in the treatment of advanced non-
small cell lung cancer (NSCLC), and have demonstrated to significantly improve …

Background Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is
a potentially life‐threatening adverse event. The purpose of this study was to evaluate …